Effective drug delivery to the central nervous system (CNS) remains a challenge due to the blood-brain barrier (BBB). Macromolecules such as proteins and peptides are unable to cross BBB and have poor therapeutic efficacy due to little or no drug distribution. A promising alternative is the conjugation of a drug to a shuttle molecule that can reach the CNS via receptor-mediated transcytosis (RMT). Several receptors have been described for RMT, such as low-density lipoprotein receptor-related protein 1 (LRP1). We used phage display technology combined with an BBB model to identify LRP1 ligands. A single domain antibody (dAb) library was used to enrich for species that selectively bind to immobilised LRP1 ligand. We obtained a novel nanobody, dAb D11, that selectively binds to LRP1 receptor and mediates internalisation of phage particles in brain endothelial cells, with a dissociation constant Kd of 183.1 ± 85.8 nM. The high permeability of D11 was demonstrated by an biodistribution assay in mice. We discovered D11, the first LRP1 binding dAb with BBB permeability. Our findings will contribute to the development of RMT-based drugs for the treatment of CNS diseases.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/1061186X.2024.2434908 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
CD91-mediated reprogramming of DCs by immunogenic heat shock proteins requires the kinases AXL and Fgr.
Cell Commun Signal
December 2024
Department of Immunology, 4035 The Assembly, 5051 Centre Ave, Pittsburgh, PA, 15213, USA.
Immune responses to tumors, comprising adaptive T cells and innate NK cells, arise very early in tumorigeneses and prior to detection of palpable tumors or before tissue pathology is evident. Yet, how nascent tumors evoke dendritic cell maturation and the resulting cytokine responses that are necessary for these effector anti-tumor immune responses is unknown. We have previously shown that CD91 expression on dendritic cells is important for immune surveillance, specifically for generating T cell and NK cell responses to nascent tumors.
View Article and Find Full Text PDFSelection of LRP1 ligand phage-displayed single domain antibody that transmigrates BBB.
J Drug Target
December 2024
Pharmacology Department, School of Biological Sciences, Recombinant Biopharmaceuticals Laboratory, University of Concepcion, Concepcion, Chile.
Effective drug delivery to the central nervous system (CNS) remains a challenge due to the blood-brain barrier (BBB). Macromolecules such as proteins and peptides are unable to cross BBB and have poor therapeutic efficacy due to little or no drug distribution. A promising alternative is the conjugation of a drug to a shuttle molecule that can reach the CNS via receptor-mediated transcytosis (RMT).
View Article and Find Full Text PDFThe Low-Density Lipoprotein Receptor-Related Protein-1 Is Essential for Dengue Virus Infection.
Viruses
October 2024
Department of System Biology, Direction of Biomedical Research, Center for Genetic Engineering and Biotechnology, Havana 10600, Cuba.
Dengue virus (DENV) causes the most prevalent and rapidly spreading arboviral disease of humans. It enters human cells by receptor-mediated endocytosis. Numerous cell-surface proteins were proposed as DENV entry factors.
View Article and Find Full Text PDFThe LDL Receptor-Related Protein 1: Mechanisms and roles in promoting Aβ efflux transporter in Alzheimer's disease.
Biochem Pharmacol
January 2025
The First Affiliated Hospital, Hunan Provincial Clinical Medical Research Center for Drug Evaluation of Major Chronic Diseases, Hengyang Medical School, University of South China, Hengyang 421001, Hunan, China; The First Affiliated Hospital, Hengyang Clinical Pharmacology Research Center, Hengyang Medical School, University of South China, Hengyang 421001, Hunan, China; The First Affiliated Hospital, Hengyang Key Laboratory of Clinical Pharmacology, Hengyang Medical School, University of South China, Hengyang 421001, Hunan, China. Electronic address:
The LDL Receptor-Related Protein 1(LRP1), a member of the Low-density Lipoprotein (LDL) receptor family, is a multifunctional cellular transporter and signaling receptor, this includes regulation of lipid metabolism, cell migration and signaling. Abnormal accumulation of amyloid beta (Aβ) in the brain is thought to be the main pathological change in Alzheimer's disease. By binding to a variety of ligands, LRP1 is involved in the internalization and degradation of Aβ, thereby affecting the course of Alzheimer's disease (AD).
View Article and Find Full Text PDFLrp1 facilitates infection of neurons by Jamestown Canyon virus.
bioRxiv
November 2024
Center for Vaccine Research, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States.
Article Synopsis
- Jamestown Canyon virus (JCV) is a type of bunyavirus that causes neuroinvasive diseases in the U.S., but its mechanism of infection is not well understood.
- Recent research identifies low-density lipoprotein receptor related protein 1 (Lrp1) as a key factor that enables JCV and other bunyaviruses to infect cells, particularly in the nervous system.
- Experiments show that neurons lacking Lrp1 have reduced JCV infection rates, suggesting that targeting Lrp1 could lead to new antiviral treatments for diseases caused by bunyaviruses.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!